APR 10, 2015 12:29 PM PDT

Biologists Identify Brain Tumor Weakness

Biologists at MIT and the Whitehead Institute have discovered a vulnerability of brain cancer cells that could be exploited to develop more-effective drugs against brain tumors.
The top two panels show tumors produced by cancer cells. The outer ring of cells (blue) has enough oxygen to survive, but not as much oxygen reaches the inner cells. At top right, tumor cells lack the SHMT2 gene and are unable to survive in this central region, as indicated by the pink stain that marks a protein produced during cell death. At top left, the cells express high levels of SHMT2, allowing some of them to survive, indicated by the blue clusters of cells. The bottom two panels are magnifications of the central tumor regions.
The study, led by researchers from the Whitehead Institute and MIT's Koch Institute for Integrative Cancer Research, found that a subset of glioblastoma tumor cells is dependent on a particular enzyme that breaks down the amino acid glycine. Without this enzyme, toxic metabolic byproducts build up inside the tumor cells, and they die.

Blocking this enzyme in glioblastoma cells could offer a new way to combat such tumors, said Dohoon Kim, a postdoc at the Whitehead Institute and lead author of the study, which appears in the April 8 online edition of Nature.

David Sabatini, a professor of biology at MIT and member of the Whitehead Institute, is the paper's senior author. Matthew Vander Heiden, the Eisen and Chang Career Development Associate Professor of Biology and a member of the Koch Institute, also contributed to the research, along with members of his lab.

GLDC caught the researchers' attention as they investigated diseases known as "inborn errors of metabolism," which occur when cells are missing certain metabolic enzymes. Many of these disorders specifically affect brain development; the most common of these is phenylketonuria, marked by an inability to break down the amino acid phenylalanine. Such patients must avoid eating phenylalanine to prevent problems such as intellectual disability and seizures.

Loss of GLDC produces a disorder called nonketotic hyperglycinemia, which causes glycine to build up in the brain and can lead to severe mental retardation. GLDC is also often overactive in certain cells of glioblastoma, the most common and most aggressive type of brain tumor found in humans.

The researchers found that GLDC, which breaks down the amino acid glycine, is overexpressed only in glioblastoma cells that also have high levels of a gene called SHMT2, which converts the amino acid serine into glycine. Those cells are so dependent on GLDC that when they lose it, they die.

Further investigation revealed that SHMT2 is expressed most highly in cancer cells that live in so-called ischemic regions - areas that are very low in oxygen and nutrients. These regions are often found at the center of tumors, which are inaccessible to blood vessels. It turns out that in this low-oxygen environment, SHMT2 gives cells a survival edge because it can indirectly influence the activity of an enzyme called PKM2, which is part of the cell's machinery for breaking down glucose.

Regulation of PKM2 can impact whether cells can generate the material to build new cancer cells, but the same regulation also affects the consumption of oxygen - a scarce resource in ischemic regions.

"Cells that have high SHMT2 activity have low PKM2 activity, and consequently low oxygen-consumption rates, which makes them better suited to survive in the ischemic tumor microenvironment," Kim said.

However, this highly active SHMT2 also produces a glut of glycine, which the cell must break down using GLDC. Without GLDC, glycine enters a different metabolic pathway that generates toxic products that accumulate and kill the cell.

"An interesting aspect of the current study is that they uncovered why glycine accumulation is toxic," said Navdeep Chandel, a professor of medicine and cellular biology at Northwestern University who was not part of the research team. "GLDC loss accumulates glycine, causing nonketotic hyperglycinaemia, a disorder that severely affects the developing brain. Sabatini and colleagues elucidated that loss of GLDC builds up glycine levels, resulting in funneling of glycine into metabolic pathways that generate toxic molecules, such as aminoacetone and methylglyoxal."

The finding also raises the possibility that these GLDC-dependent cells could be killed with drugs that block GLDC activity, according to the researchers, who are now seeking potential drug compounds that could do just that.

Source: MIT
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
OCT 21, 2019
Drug Discovery & Development
OCT 21, 2019
Anti-cancer Drug Disguises as Fat
According to a study published in the Journal of the American Chemical Society (JACS), a new drug-delivery system disguises as fat in order to outsmart tum...
OCT 21, 2019
Cancer
OCT 21, 2019
New hope for ovarian cancer
Ovarian cancer affects roughly 1 in 78 women and although survival rates are high (over 90%) with early diagnosis, we currently do not have a way to test f...
OCT 21, 2019
Cancer
OCT 21, 2019
How cancer tricks our immune systems
Research published yesterday in Nature details the finding of a new “Don’t eat me” signal that cancers use to hide from the body’s ...
OCT 21, 2019
Cancer
OCT 21, 2019
Antibiotic use associated with bowel cancer
From 2000–2010, global consumption of antibiotics rose by 35% up to 70 billion doses each year. Although doctors are more cautious to prescribe antib...
OCT 21, 2019
Cancer
OCT 21, 2019
It's not all bad: cancer and aging
Research published recently in the journal Aging Cell highlights the complexities of the interactions that occur during the aging process from the angle of...
OCT 21, 2019
Cancer
OCT 21, 2019
New hope for mesothelioma treatment
Mesothelioma is a very rare kind of malignant tumor that is caused by inhaled asbestos fibers and forms in the lining of the lungs, abdomen or heart. While...
Loading Comments...